Neogrand (Clodronate Disodium Tetrahydrate)

Clodronate binds to hydroxyapatite in bone and is internalised by osteoclasts during resorption. Inside the cell it is converted to a non‑hydrolyzable ATP analogue that induces osteoclast apoptosis, thereby decreasing bone breakdown and stabilising skeletal integrity.

The specific dose of Neogrand is determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for clodronate during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Neogrand product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Neogrand (clodronate) is a non‑nitrogenous bisphosphonate, whereas agents such as alendronate or zoledronic acid are nitrogen‑containing and generally more potent. Clodronate may be preferred in certain clinical scenarios because of its distinct metabolic pathway and safety profile, but efficacy and choice depend on individual patient needs.

Neogrand should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Neogrand is taken orally, usually with a full glass of water. It is recommended to swallow the tablet whole and avoid lying down for at least 30 minutes after ingestion. Patients should follow any specific timing instructions provided by their prescriber, such as taking it on an empty stomach.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe hypocalcaemia and acute renal impairment. Patients should report any persistent jaw pain, unusual thigh or groin pain, signs of low calcium (muscle cramps, tingling) or changes in urine output to their healthcare provider promptly.

Neogrand is contraindicated in patients with known hypersensitivity to clodronate or any excipients, severe renal impairment (creatinine clearance <30 mL/min), and in individuals with active dental infections requiring invasive procedures. Caution is also advised for pregnant or breastfeeding women, and the drug should be avoided in those with uncontrolled electrolyte disturbances.